NASDAQ:ROIV

Roivant stock set for new test after big move on drug data
·····

Roivant stock set for new test after big move on drug data

Roivant Sciences shares rose 1.2% to $30.31 in light premarket trading Tuesday after last week’s 14% surge on positive IMVT-1402 drug data. Immunovant, developing the autoimmune drug, jumped 31% last week despite reporting a larger loss than expected. BofA raised its price target to $31.50 but kept a Neutral rating, while Citi and TD Cowen lifted targets and maintained Buy calls. U.S. markets reopened after the Memorial Day holiday.
May 26, 2026

Stock Market Today

  • Chorus 2025 Regulatory Report: Regulated Asset Base Increases, Revenue Falls Short
    May 28, 2026, 8:11 PM EDT. Chorus Ltd's 2025 fibre regulatory report shows a rise in its Regulated Asset Base (RAB) to $6.0 billion, up from $5.9 billion in 2024. The company's Core RAB also increased by $0.2 billion to $5.1 billion. However, 2025 revenues were $101 million below the maximum allowed, leading to a wash-up balance of $76.3 million carried into the next regulatory period. Operating costs for the year totaled $191 million, with capital expenditure at $307 million, reflecting ongoing investments in New Zealand's fibre network. Chorus' financials and regulatory figures remain under Commerce Commission review. The company's shares have declined 8% over the past year, underperforming the ASX 200 index, which gained 2%. Chorus aims to optimize its regulatory position and continue network upgrades amid future reviews.